The current recommended urine protein to creatinine ratio is arbitrary, and a lower bar would capture more lupus nephritis ...

Persons with toxic gain-of-function variants in the gene encoding apolipoprotein L1 (APOL1) are at greater risk for the development of rapidly progressive, proteinuric nephropathy. Despite the known ...

Investigators employed the Accelerating Medicines Partnership to identify noninvasive biomarkers of lupus nephritis pathology and treatment response.

The randomized, open-label INSHORE trial (ClinicalTrials.gov Identifier: NCT05627557) evaluated the safety and efficacy of obinutuzumab in children and young adults in clinical remission aged 2 to 25 ...

Fibrosis occurs when inflammation activates immune cells and fibroblasts to release collagen and cytokines that remodel and ...

The Food and Drug Administration (FDA) has approved Gazyva ® (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

A proliferation-inducing ligand (APRIL) is implicated in the pathogenesis of IgA nephropathy. Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and neutralizes APRIL. In this phase 2 ...

Small amounts of protein can appear in your urine and be OK. Above a certain level, however, may indicate proteinuria, which can be a red flag for kidney disease. Proteins are among the most important ...